Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study
Open Access
- 1 June 2023
- journal article
- research article
- Published by Taylor & Francis in Clinical Epidemiology
- Vol. ume 15, 775-783
Abstract
Background and Aims: Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk. Methods: Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region. Results: Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8– 8.6) in baseline NSBB users vs 11.6% (95% CI 7.0– 15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3– 0.8) and after adjustment to 0.7 (95% CI 0.4– 1.3). Conclusion: NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.Keywords
This publication has 20 references indexed in Scilit:
- The chronic use of beta‐blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosisLiver International, 2014
- Ascites and spontaneous bacterial peritonitis: Recommendations from two United States centersSaudi Journal of Gastroenterology, 2014
- Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-BlockersAdvances in Therapy, 2013
- Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experienceScandinavian Journal of Gastroenterology, 2013
- Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosisJournal of Hepatology, 2013
- Altered intestinal tight junctions’ expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeabilityEuropean Journal of Clinical Investigation, 2011
- Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severityGut, 2011
- Infections in Patients With Cirrhosis Increase Mortality Four-Fold and Should Be Used in Determining PrognosisGastroenterology, 2010
- 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions ConferenceCritical Care Medicine, 2003
- Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in SepsisChest, 1992